Form 4: United Therapeutics Director Sells Shares Under 10b5-1 Plan
Insider Transaction Report
A director at United Therapeutics Corporation sold 50 shares of common stock for $460.98 per share under a pre-arranged trading plan.
Summary
- Jan Malcolm, a Director of United Therapeutics Corporation (UTHR), reported a sale of common stock.
- The transaction involved the disposition of 50 shares of common stock.
- The shares were sold at a price of $460.98 per share.
- The sale occurred on January 16, 2026.
- This transaction was executed pursuant to a Rule 10b5-1 trading plan, which was established by the reporting person on September 11, 2025.
- Following this transaction, Jan Malcolm directly beneficially owns 320 shares of United Therapeutics Corporation common stock.
Sentiment
Score: 5
Explanation: Neutral, as it reports a pre-scheduled insider stock sale, which is a routine disclosure and not inherently positive or negative for the company's operational performance.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
NA
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Minimal immediate impact on shareholders as the sale was pre-planned and a relatively small number of shares.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 09/11/2025 | Date Rule 10b5-1 trading plan was entered into by the reporting person. |
| 01/16/2026 | Date of the reported transaction (sale of common stock). |
| 01/20/2026 | Date the Form 4 filing was signed. |
Recommendation
holdThe filing reports a routine, pre-scheduled sale of a small number of shares by a director under a Rule 10b5-1 plan. This type of transaction is typically not indicative of a change in the company's fundamentals or future prospects and does not warrant a change in investment recommendation based solely on this disclosure.
Keywords
United Therapeutics, UTHR, Insider Trading, Form 4, Stock Sale, Director, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.